Probiotix Health (AQSE:PBX) Selling, General, & Admin. Expense: £0.69 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AQSE:PBX Probiotix Health PLC AQSE:PBX
27 GF Score
Price £0.11
GF Value £0.09
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Probiotix Health Selling, General, & Admin. Expense?

Probiotix Health AQSE:PBX 27 Selling, General, & Admin. Expense is £0.69 Mil as of Dec. 2025. GuruFocus rates AQSE:PBX with a GF Score™ of 27/100 and a GF Value™ of £0.09 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Probiotix Health's selling, general, & admin. expense for the six months ended in Dec. 2025 was £-0.17 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was £0.69 Mil.


Probiotix Health  (AQSE:PBX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Probiotix Health Selling, General, & Admin. Expense Related Terms


Probiotix Health Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Probiotix Health's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Probiotix Health Selling, General, & Admin. Expense Chart

Probiotix Health Annual Data
Trend Dec18 Dec19 Dec20 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 0.09 0.00 0.73 0.78 0.69

Probiotix Health Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.80 -0.02 0.86 -0.17

AQSE:PBX vs VRTX, REGN, MRNA: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Probiotix Health's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Probiotix Health Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Probiotix Health's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Probiotix Health's Selling, General, & Admin. Expense falls into.


AQSE:PBX
27GF Score
Probiotix Health PLC AQSE:PBX
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Probiotix Health Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of £0.69 Mil mean?
Probiotix Health (AQSE:PBX) has a Selling, General, & Admin. Expense of £0.69 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Probiotix Health and its competitors.
Is Probiotix Health's Selling, General, & Admin. Expense too high?
Probiotix Health's current Selling, General, & Admin. Expense is £0.69 Mil. Overall, Probiotix Health has a GF Score™ of 27/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Probiotix Health's Selling, General, & Admin. Expense compare to VRTX and REGN?
Probiotix Health's Selling, General, & Admin. Expense of £0.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Probiotix Health and its competitors. Probiotix Health's current Selling, General, & Admin. Expense is £0.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Probiotix Health stock overvalued right now?
Based on GuruFocus' analysis, Probiotix Health (AQSE:PBX) is currently considered Modestly Overvalued. The stock's GF Value™ is £0.09, compared to a current price of £0.11 — trading 16.7% above its estimated fair value. The current Selling, General, & Admin. Expense is £0.69 Mil. Probiotix Health's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Probiotix Health (AQSE:PBX), the current Selling, General, & Admin. Expense is £0.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Probiotix Health (AQSE:PBX) Overvalued in 2026?

Based on GuruFocus' analysis, Probiotix Health stock appears to be overvalued. The current stock price of £0.11 is trading 16.7% above its estimated GF Value™ of £0.09. GuruFocus considers Probiotix Health to be Modestly Overvalued.

Key valuation signals for AQSE:PBX:

  • Selling, General, & Admin. Expense: £0.69 Mil
  • GF Value™: £0.09 vs. price of £0.11 (16.7% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the AQSE:PBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Probiotix Health Business Description

Address Nostell Business Estate, First Floor Zucchi Suite, Wakefield, GBR, WF4 1AB
Probiotix Health PLC is a life sciences company that develops probiotics to tackle cardiovascular disease and other lifestyle conditions that are affecting growing numbers of people across the world. The company has one class of business, in three geographical areas, being that of identifying and developing microbial strains, compounds and formulations for use in the nutraceutical industry. Its geographical segments include the United Kingdom, the United States, and the Rest of the World. It generates the majority of its revenue from the United States.
27GF Score

Get the complete analysis for AQSE:PBX

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.11
Price
£0.09
GF Value